# Compugen Secures $90M Gilead Deal and Advances Ovarian Cancer Trial

- URL: https://stocks.freetheai.org/news/compugen-secures-90m-gilead-deal-and-advances-ovarian-cancer-trial-d6d597
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NASDAQ:CGEN](https://stocks.freetheai.org/symbols/NASDAQ-CGEN)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biotechnology firm Compugen Ltd. (NASDAQ:CGEN) secured a licensing agreement with Gilead Sciences for its candidate drug GS-0321, an IL-18 binding protein. Under the agreement, Compugen received an upfront payment of $90 million and remains eligible for up to $758 million in additional milestone payments, alongside future sales royalties.

In addition to the licensing deal, Compugen is progressing its internal clinical pipeline. The company is evaluating COM701, an anti-PVRIG antibody, as a maintenance monotherapy treatment in the MAIA-ovarian clinical trial for patients with platinum-sensitive ovarian cancer. To further support research efforts, the firm launched UniGenX, an extension of its UniGen platform designed to discover tumor-associated antigens by screening diverse data types with target selectivity features.

Investors will be watching for clinical milestones as the company advances its pipeline. Compugen expects to report an interim progression-free survival readout from the MAIA-ovarian trial in the first quarter of 2027. Shares of Compugen Ltd. were trading at 2.13 USD, up 0.47%.

## Key points

- Compugen Ltd. received $90 million upfront from Gilead for licensing rights to GS-0321, with up to $758 million potential milestones plus future royalties.
- The company is evaluating COM701 as a maintenance therapy in the MAIA-ovarian trial for platinum-sensitive ovarian cancer.
- Compugen expects an interim progression-free survival readout from the MAIA-ovarian study in the first quarter of 2027.
- Compugen launched UniGenX, an expanded platform that uses logic gating to improve tumor-associated antigen discovery.

## Questions and answers

### How much upfront cash did Compugen receive from Gilead?

Compugen received $90 million upfront from Gilead for the licensing rights to GS-0321, with eligibility for up to $758 million in additional milestone payments plus royalties.

### When will Compugen report interim data for COM701 in ovarian cancer?

Compugen expects an interim progression-free survival readout from the MAIA-ovarian trial for COM701 in the first quarter of 2027.

### What is Compugen's UniGenX platform?

UniGenX expands the UniGen platform by screening multiple data types for tumor-associated antigens using logic gating to increase target selectivity and coverage.